Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Zenas Biopharma Inc (ZBIO)

Zenas Biopharma Inc (ZBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,113,074
  • Shares Outstanding, K 53,679
  • Annual Sales, $ 5,000 K
  • Annual Income, $ -156,990 K
  • EBIT $ -194 M
  • EBITDA $ -194 M
  • 60-Month Beta -1.62
  • Price/Sales 422.78
  • Price/Cash Flow N/A
  • Price/Book 8.44

Options Overview Details

View History
  • Implied Volatility 109.82% (+7.11%)
  • Historical Volatility 69.05%
  • IV Percentile 47%
  • IV Rank 37.78%
  • IV High 163.84% on 09/04/25
  • IV Low 77.01% on 11/12/25
  • Expected Move (DTE 10) 2.64 (6.76%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 94
  • Volume Avg (30-Day) 52
  • Put/Call OI Ratio 0.57
  • Today's Open Interest 1,506
  • Open Int (30-Day) 1,714
  • Expected Range 36.34 to 41.61

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.29
  • Number of Estimates 3
  • High Estimate 1.52
  • Low Estimate -2.06
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.26 +21.23%
on 11/11/25
41.50 -5.76%
on 12/08/25
+5.50 (+16.36%)
since 11/07/25
3-Month
18.24 +114.42%
on 09/16/25
41.50 -5.76%
on 12/08/25
+17.27 (+79.08%)
since 09/09/25
52-Week
5.83 +570.84%
on 01/28/25
41.50 -5.76%
on 12/08/25
+29.09 (+290.32%)
since 12/09/24

Most Recent Stories

More News
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Zenas BioPharma, Inc. (NASDAQ: ZBIO)

NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Zenas BioPharma, Inc. (NASDAQ: ZBIO) on behalf of the company's shareholders. The investigation...

ZBIO : 38.78 (-1.50%)
Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

- Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 - - Reported highly positive 12-week primary endpoint results from Phase...

ZBIO : 38.78 (-1.50%)
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences

WALTHAM, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader...

ZBIO : 38.78 (-1.50%)
How Royalty Pharma Prints Cash Without Biotech's Biggest Risks

Royalty Pharma's recent deals for promising new therapies highlight its unique and successful strategy of funding blockbuster innovation for long-term growth.

RPRX : 38.28 (-1.01%)
ZBIO : 38.78 (-1.50%)
VRTX : 440.42 (-0.37%)
AMGN : 316.69 (-1.41%)
1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data

Zenas BioPharma's stock is up after landmark clinical data for its MS drug obexelimab validated its unique science and funded a two-franchise strategy.

RPRX : 38.28 (-1.01%)
ZBIO : 38.78 (-1.50%)
INCPF : 2.1300 (-7.79%)
Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis

- Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009 - WALTHAM, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Zenas...

ZBIO : 38.78 (-1.50%)
Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis

- Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009 - WALTHAM, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Zenas...

ZBIO : 38.78 (-1.50%)
Zenas BioPharma Secures Licensing Deal with InnoCare

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...

ZBIO : 38.78 (-1.50%)
Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis

- Orelabrutinib, a highly selective CNS-penetrant, oral small molecule Bruton’s Tyrosine Kinase (BTK) inhibitor with best-in-class potential now in Phase 3 development for progressive forms of Multiple...

ZBIO : 38.78 (-1.50%)
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

- Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease - - Additional $150 million associated with the upcoming results of the...

RPRX : 38.28 (-1.01%)
ZBIO : 38.78 (-1.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Zenas BioPharma Inc. is a clinical-stage global biopharmaceutical company. It involved in the development and commercialization of transformative immunology-based therapies for patients in need. The company's lead product candidate includes obexelimab and Fc'RIIb. Zenas BioPharma Inc. is based in WALTHAM,...

See More

Key Turning Points

3rd Resistance Point 43.09
2nd Resistance Point 42.29
1st Resistance Point 40.83
Last Price 38.78
1st Support Level 38.57
2nd Support Level 37.78
3rd Support Level 36.31

See More

52-Week High 41.50
Last Price 38.78
Fibonacci 61.8% 27.87
Fibonacci 50% 23.67
Fibonacci 38.2% 19.46
52-Week Low 5.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar